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1Chapter
The Rational Drug Design to Treat 
Cancers
Abdul Hameed Khan
Abstract
Professor Ross of London University, England, was using nitrogen mustard to 
treat cancers by attacking both strands of tumor DNA. As a part of my doctoral 
thesis, I am to design drugs using aziridine to attack only one strand of DNA. 
Over the years, I made over 100 dinitrophenyl aziridine derivatives. One of them 
is dinitrobenzamide (CB1954) which gives a CI of 70, highest toxicity to animal 
tumor ever recorded. CB1954 wipes out a solid aggressive tumor by attacking a 
single-strand DNA of Walker carcinoma 256, in rat. My greatest challenge at NCI in 
USA is to translate the animal work which I did in London University to humans. As 
radiolabeled methylated quinone crosses the blood-brain barrier in mice, I decided 
to use quinone moiety as a carrier for aziridine rings to attack glioblastomas, the 
brain tumor in humans. By attaching two aziridines and two carbamate moieties to 
quinone, I made AZQ (US Patent 4,146,622). By treating brain cancer with AZQ , we 
observed that glioblastoma tumor not only stops growing but also starts shrinking. 
Literature search showed that AZQ is extensively studied.
Keywords: drug design, tumor treatment, novel drugs for cancer treatment
1. Introduction
Rational drug design is absolutely essential for developing novel drugs for 
treating any disease, especially cancers. Our Institute, the NIH (National Institutes 
of Health is an agency of US Government) learned this fact by spending enormous 
amount of money over the years by testing known and unknown products obtained 
by synthesis or from plants and animals on a variety of testing tumor systems. The 
discovery of a handful of drugs by trial and errors at a cost of millions was consid-
ered a waste of time and money. In early days, we absorbed the losses because our 
Institute, located about 10 miles from Washington, DC, is the largest biomedical 
center in the world. Our annual budget is over 40 billion dollars per year. Over 26 
institutes have about 3000 labs where about 21,000 scientists work in 50 buildings. 
My lab was in the National Cancer Institute (NCI), which is the largest among all 
institutes and it has a budget of over 5 billion dollars per year. Now, we became 
more cautious screening drugs. About 20% of our budget is spent in-house and 
the 80% of our budget is provided to research labs around the world by reviewing 
their research projects by expert panels called the study sections to approve funds to 
projects most rational and most likely to be accomplished.
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2. Genomic medicine
This chapter describes the novel drug design based on the genetic makeup of 
a patient. My main focus is on two major areas, and they are diagnostic and novel 
drug design to treat these diseases. Today, we are treated with the same medicine for 
the same disease as if we all have the identical genomes. In fact, no two people look 
alike and no two genomes are alike. Our genome is made of six billion four hundred 
million nucleotides, and in almost every 1000 nucleotides, we find a variant and 
in the entire script, we find 3.4 million variants called the SNP (single-nucleotide 
polymorphism). Each of us has a unique genetic makeup and requires the develop-
ment of a specific medicine to treat that disease. This concept is now known as the 
pharmacogenomic, and it provides a paradigm shift in drug design.
To design a genomic medicine, first we need to sequence the whole genome iden-
tifying specific region (genes) which codes for specific proteins. Second, we need to 
sequence as many genomes as possible (such efforts are undergoing as a Thousand 
Genome Project, a Million or a Three Million Genome Project) to compare their 
sequences to identify differences called variants. Then, we need to develop next 
generation of sequencers to sequence everyone’s genome as cheaper and as faster 
as possible. Next, we need to identify the differences in the genetic scripts, and 
then, we need to separate bad or abnormal mutated variants responsible for caus-
ing diseases. Next, we need to identify rare variants as diagnostic tools responsible 
for causing rare diseases (young people diseases) such as Parkinson, Huntington, 
cystic fibrosis, muscular dystrophy, color blindness, sickle cell anemia, etc. called 
the monogenic or Mendelian diseases. Next, we need to identify the common 
genetic diseases (old people diseases) such as cancers, cardiovascular diseases, 
and Alzheimer. First, we generate sequence data and then by comparing we find a 
correlation between variants and diseases. We can construct a correlation map of all 
variants responsible for causing all genetic disorders. After diagnosing the diseases, 
the next most important step is to treat those diseases by novel drug design.
Our work below describes over a quarter of a century’s effort by first design-
ing drugs to shut off genes responsible for causing cancers in animals and then we 
further describe how we translated the animal work in humans. The following pages 
describe the development of genomic medicine based on the drug design and on the 
genetic makeup of a patient. I will cover three areas. First, I will provide historical 
background which describes the early development of medicines to treat diseases. 
Second, I will describe the rational drug design to treat abnormal mutated genes 
and the specific nucleotide identified by the human genome sequencing to develop 
new drugs to treat old diseases, and finally, I will discuss the ethical problems in 
an attempt to answer the consequences of prolonging human life on planetary 
resources and environment.
3. Historical background
Since the dawn of human civilization, achieving human longevity has been 
the dream of every King, every Queen, every Pharos, and every Caesar. But they 
all died in their 50s by infectious diseases. Then came the science and technol-
ogy revolution. In 1928, Alexander Flaming, while working on influenza virus, 
observed that a mold had developed accidently on a staphylococcus culture plate. 
By killing the bacteria, the mold had created a bacteria-free circle around itself. 
He was so inspired by the presence of the bacterial free zone that he conducted 
further experiment and found that the mold culture produced a substance which 
prevented growth of staphylococci, even when diluted 800 times. He named the 
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active substance penicillin. The discovery of penicillin [1] was followed by a host 
of new antibiotics such as streptomycin, neomycin, kanamycin, paromomycin, 
apramycin, tobramycin, amikacin, netilmicin, and gentamicin and dozens of their 
derivatives which wipeout Gram-positive and Gram-negative bacteria. Misuse 
and overuse of antibiotics in agriculture resulted in the bacterial resistance. For 
example, farmers overuse the antibiotics in food-producing animals not only to 
kill the bacteria in cows, goat, and chicken farms but also use to promote growth in 
these animals exposing excessive amount of antibiotics residues to humans in their 
food. We developed a spectroscopic method [2] to detect their residue in PPT (parts 
per trillion) to provide safe food for consumption.
We conquered infectious diseases. We increased our life span from 50 to 
60 years. Then came the genetic revolution. We broke the genetic code and 
unlocked the secrets of life. Now, we are ready to manipulate life not only to clean 
up our environmental pollution but also to produce new food, new fuel, and new 
medicine to treat every disease known to mankind. We also succeeded in increasing 
human lifespan beyond 60 to 70 years.
Next, we read the entire book of human life. We read the total genetic informa-
tion that makes the human life; we completed the Human Genome Project. Next, 
we sequenced the human genome, that is, we read the number of nucleotides and 
the order in which they are arranged. With advancement in science and technology, 
we sequenced the human genome cheaper and faster using the next-generation 
sequencers such as nanopore. Then, we completed the 1000 Human Genome 
Project. We are able to compare the reference sequence of every gene with the 
1000 copies of the same gene from different individuals to identify differences. 
These differences are called variants. If the good variant came from the pancreas, 
it produces insulin which is used to treat diabetes. If the variant came from an 
abnormal mutated gene, it is responsible for causing common diseases such as 
cancers, cardiovascular diseases, or Alzheimer. Soon, we will prepare a variant map 
of the entire genome to identify all 6000 diseases; then, we can design drugs to treat 
these diseases by shutting off their genes. The Thousand Genome Project will help 
us single out the rare mutation responsible for causing rare genetic diseases such 
as Parkinson with precision and accuracy. With advent of new technologies, we 
embark on the more ambitious project such as The Human Brain Project and The 
Human Longevity Project.
Next, I will attempt to answer an important question about how to design 
drugs to treat diseases to save human life by using the information available from 
the Human Genome Project. How many diseases we inherit from our parents? We 
identified good and bad genes in our genome. We wonder if bad mutations are writ-
ten on our DNA. Is the secret hidden in the long string of four nucleotides text on a 
three-letter codon carrying 24,000 genes in 46 chromosomes in our genome con-
taining six billion four hundred million nucleotides? Could we identify the genetic 
variants responsible for our diseases by comparing the whole-genome sequence 
of the centenarians with the 1000 Human Genome Project completed by US and a 
Million Human Genome Project to be completed by European and a three Million 
Human Genome Project announced by the Chinese to identify rare alleles responsi-
ble for causing rare diseases with accuracy and precision. We want to identify in the 
whole genome the specific genetic variations and the few nucleotides responsible 
for our health. As I said above, before the discovery of antibiotics, most people died 
in their 50s. Today, all infectious diseases are treated with antibiotics. Now, we must 
treat the old age common diseases such as cancers, cardiac diseases, and Alzheimer. 
To save human life from these dreadful diseases, we have to design drugs to shut 
off genes responsible for causing these old age diseases. Next, I will describe how 
I design drugs to shut off genes which cause brain cancer, glioblastomas. Similar 
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rationale could be used to design drugs to shut off genes responsible for causing 
cardiovascular diseases and Alzheimer.
4. Genotype-phenotype correlations
Our genes are units of inheritance and carry instructions to make proteins, and 
when the proteins fold, they become reactive and carry out a specific function. 
Hundreds of proteins interact to make a cell, and millions of cells interact to make a 
tissue. Hundreds of tissues interact to make an organ, and several organs interact to 
make a human being. We carry in our body 220 different tissues. The instructions 
to make tissues are written in our genes. A defected tissue could be identified by 
looking at the mutation in the genes. We can prevent diseases at a very early stage 
of our lives. By sequencing a fertilized egg, the genotype, we could identify the 
mutations responsible for future diseases in tissues, the phenotype. If a patient has 
a family history of a specific disease, to prevent future generation from inheriting 
the disease, it is best advice for such families to have conception by in vitro fertiliza-
tion after making sure that the fertilized egg is free from all abnormal mutations 
responsible for causing the disease.
Our entire genome, the book of our life, is written in four nucleotides, and they 
are A (adenine), T (thiamine), G (guanine), and C (cytosine). The chain of these 
nucleotides forms a double-stranded string of nucleotides, one strand is inherited 
from our mother and another from our father, running in opposite directions called 
the DNA (deoxyribonucleotide). According to Francis Crick’s Central Dogma [3], 
double-stranded DNA is transcribed into a single-stranded RNA which is translated 
in the ribosome into proteins. The discovery of the double helical structure of DNA 
explained how the information to create life is stored, replicate, evolved, and passed 
on to the next generation. This discovery opened a new world order of ideas and 
buried the old explanation of the magical mystical appearance of life on Earth.
The double-stranded DNA explained that the essence of life is information and 
the information is located on these four nucleotides. Every set of three nucleotides 
on the mRNA forms a codon which codes for a specific amino acid. The four-letter 
text of nucleotides forms a three-letter codon which codes for an amino acid. 
There are 64 different combinations of codons which codes for all 20 amino acids. 
Sequencing human genome identifies the number of nucleotides and the order in 
which they are arranged. Less than 2% of our genome contains regulatory region, 
a piece of DNA, which controls the function of genes. More than 300 regulatory 
regions have been identified. More than 98% of our genome contains non-coding 
region used to be called the junk DNA which makes up to 60% of our entire 
genome. The non-coding regions contains repetitive piece of DNA, which is tightly 
packed and mostly remain silent. The sequencing of this region showed that the 
non-coding region is the part of viruses and bacteria picked up by our genome 
during the millions of years of our evolutionary process. During bacterial or viral 
infection, the non-coding DNA could unfold transcribing into RNA resulting into 
hazardous protein which could create havoc for our health.
Genes are the unit of inheritance. As I said above, out of four-letter text, that is 
A-T and G-C, and three letters code for an amino acid called the codon. The start-
ing codon in a gene is the codon AUG (instead of T nucleotide, we use U nucleotide 
because thiamin is converted to more water-soluble uracil), which codes for amino 
acid methionine. Long chain of DNA synthesis begins. The starting codon is fol-
lowed by a series of hundreds of codons which codes for different amino acids in 
different species. There are three stop codons, and they are AUG, UGG, and UGA. 
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Once the stop codons appear, DNA synthesis stops. Bacteria and viruses have short 
codon chain. The longest chain is in a gene of Duchenne muscular dystrophy, a neu-
rological disease whose chain extends to two and a half million codons. Once a gene 
is identified, using restriction enzymes, like EcoR1, we can cut, paste, and copy 
all genes individually making a restriction site map. Once a single gene is isolated, 
we could compare the sequence of this gene with the Thousand Genome Project to 
identify abnormal mutation responsible for the disease and design drugs to shut off 
that gene. Sequencing is like extracting gold from its ore.
Let us examine the sequence of the genome of human egg and sperm. An egg 
contains a single strand of 164 million nucleotide bases carrying 1144 genes, while 
the human sperm contains a single strand of 59 million nucleotide bases carrying 
214 genes. When comparing the sequence of an egg or sperm with sequence of 
the 1000 eggs and sperms of different people, we notice changes. These changes 
are called variants. These variants are mutations caused by radiations, chemical 
and environmental pollution, viral infection, or genetic inheritance resulting in 
rare diseases. Once a bad gene is identified, sequencing will identify the abnor-
mal nucleotide. Now, we can design drug to bind to this nucleotide and shut off 
its function. We present in the “Cancers” section below a novel drug design. 
Using aziridines and carbamate how we design drugs to shut off these genes to 
restore health.
Although we are allowed to shut off and remove bad genes, we are not allowed to 
introduce good genes in the egg and sperm to enhance the abilities of egg and sperm 
because modification introduced in the egg and sperm will pass on to the next 1000 
generations. For this reason, germ line gene therapy is forbidden in all countries. At 
this time, we cannot answer a simple question. Are we to determine the quality of 
life of individuals who will not even be born before the century is over?
We cannot design novel drugs unless we find the abnormal mutations responsi-
ble for causing that disease. The reading of the total genetic information that makes 
us human is called the human genome. The reading of the entire book of our life is 
authorized by the US Congress under The Human Genome Project. It will answer 
the most fundamental question we have asked ourselves since the dawn of human 
civilization. What does it mean to be human? What is the nature of memory and 
our consciousness? Our development from a single cell to a complete human being? 
The biochemical nature of our senses and the process of our aging? The scientific 
basis of our similarity and dissimilarity: similarity is that all living creatures from a 
tiny blade of grass to the mighty elephant including man, mouse, monkey, mosqui-
tos, and microbes are all made of the same chemical building blocks, yet we are so 
diverse that no two individuals are alike even identical twins are not exactly identi-
cal, they grow up to become two separate individuals.
In 1990, US Congress authorized 3 billion dollars to NIH to decipher the entire 
human genome under the title, “The Human Genome Project.” We found that our 
genome contains six billion four hundred million nucleotide bases, half comes 
from our father and another half comes from our mother. Less than 2% of our 
genome contains genes which code for proteins. The other 98% of our genome 
contains switches, promoters, terminators, etc. The 46 chromosomes present in 
each cell of our body are the greatest library of the Human Book of Life on planet 
Earth. The chromosomes carry genes which are written in nucleotides. Before 
sequencing (determining the number and the order of the four nucleotides on a 
chromosome), it is essential to know how many genes are present on each chro-
mosome in our genome. The Human Genome Project has identified not only the 
number of nucleotides on each chromosome but also the number of genes on each 
chromosome [4–8].
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The following list provides the details composition of each chromosome includ-
ing the number of nucleotides and the number of genes on each chromosome.
We found that chromosome-1 is the largest chromosome carrying 263 million 
A, T, G, and C nucleotide bases and has only 2610 genes. Chromosome-2 contains 
255 million nucleotide bases and has only 1748 genes. Chromosome-3 contains 
214 million nucleotide bases and carries 1381 genes. Chromosome-4 contains 
203 million nucleotide bases and carries 1024 genes. Chromosome-5 contains 
194 million nucleotide bases and carries 1190 genes. Chromosome-6 contains 
183 million nucleotide bases and carries 1394 genes. Chromosome-7 contains 
171 million nucleotide bases and carries 1378 genes. Chromosome-8 contains 
155 million nucleotide bases and carries 927 genes. Chromosome-9 contains 
145 million nucleotide bases and carries 1076 genes. Chromosome-10 contains 
144 million nucleotide bases and carries 983 genes. Chromosome-11 contains 
144 million nucleotide bases and carries 1692 genes. Chromosome-12 contains 
143 million nucleotide bases and carries 1268 genes. Chromosome-13 contains 
114 million nucleotide bases and carries 496 genes. Chromosome-14 contains 
109 million nucleotide bases and carries 1173 genes. Chromosome-15 contains 
106 million nucleotide bases and carries 906 genes. Chromosome-16 contains 
98 million nucleotide bases and carries 1032 genes. Chromosome-17 contains 
92 million nucleotide bases and carries 1394 genes. Chromosome-18 contains 
85 million nucleotide bases and carries 400 genes. Chromosome-19 contains 
67 million nucleotide bases and carries 1592 genes. Chromosome-20 contains 
72 million nucleotide bases and carries 710 genes. Chromosome-21 contains 50 
million nucleotide bases and carries 337 genes. Chromosome-22 contains 56 mil-
lion nucleotides and carries 701 genes. Finally, the sex chromosome of all female 
called the (X) contains 164 million nucleotide bases and carries 1141 genes. 
The male sperm chromosome contains 59 million nucleotide bases and carries 
255 genes.
If you add up all genes in the 23 pairs of chromosomes, they come up to 26,808 
genes and yet we keep on mentioning 24,000 genes needed to keep us function 
normally. As I said above, a gene codes for a protein, not all 24,000 genes code for 
proteins. It is estimated that less than 19,000 genes code for protein. Because of 
the alternative splicing, each gene codes for more than one protein. All functional 
genes in our body make less than 50,000 proteins which interact in millions 
of different ways to give a single cell. Millions of cells interact to give a tissue, 
hundreds of tissues interact to give an organ, and several organs interact to make 
a human.
Not all genes act simultaneously to make us function normally. Current studies 
show that a minimum of 2000 genes are enough to keep human function normally; 
the remaining genes are backup support system and they are used when needed. 
The non-functional genes are called the pseudo genes. For example, millions of 
years ago, humans and dogs shared some of the same ancestral genes; we both 
carry the same olfactory genes, only in dogs, they still function to search for food. 
Since humans do not use these genes to smell for searching food, these genes are 
broken and lost their functions, but we still carry them. We call them pseudo genes. 
Recently, some Japanese scientists have activated the pseudo genes; this work may 
create ethical problem in future as more and more pseudo genes are activated. 
Nature has good reasons to shut off those pseudo genes.
Next, we converted the analog language biology to the digital language of com-
puter, that is, from A-T and G-C nucleotides to numbers 0 and 1. Now, we can write 
a program and design a computer to read the book of life faster and faster. Today, 
we can read our entire genome in 1 day at a cost of 1000 dollars. We can also upload 
7The Rational Drug Design to Treat Cancers
DOI: http://dx.doi.org/10.5772/intechopen.93325
our digitized genome on the computer. Once uploaded on the Website, our genome 
could travel with the speed of light to anywhere in the world or in the universe.
Once the good and bad genes are identified, we learned that the good genes code 
for good proteins which keep us healthy and the bad genes produce bad proteins 
that make us sick. Using good genes, we make good protein to treat diseases such 
as insulin is used to treat diabetes. On the other hand, we could identify bad gene 
and design drugs to shut off bad genes to prevent diseases. This starts a new era of 
genomic medicine based on differences of the genetic make of each individual.
The double-stranded DNA in the normal cell, the autosome, is retained with the 
individual. When the person dies, the genome dies with him. On the other hand, 
the DNA in a germ line cell lives on for generations. Through egg and sperm cells, 
the DNA is passed on to the future generations, that is, the information is passed on 
from parents to the fetus in different combinations for generation after generation.
A sperm, the Y-chromosome, is made of a single string of 59 million nucleotide 
bases and carry 231 genes, while an egg, the X-chromosome, is made of a single 
string of 164 million nucleotide bases and carry 1144 genes. Neither two sperms 
nor any two eggs are alike. Once the egg is fertilized, the nucleotides and genes are 
exchanged (recombination occurs) among nucleotides forming a double-stranded 
DNA. Now, each string is a complete genome. During replication, each string sepa-
rates and picks up the complimentary nucleotide bases (such as nucleotide A picks up 
T and G picks up C) from the nucleotide pool and forms two double-stranded DNA 
forming two daughter cells. The two strands of each chain run in opposite directions.
5. Reactive and predictive medicine
Reactive medicine is the treatment of a disease after its symptoms are revealed 
and the full-blown disease appears. During your annual health checkup, your 
physicians order a number of tests. For example, if you are a 40-year-old male and 
go to the doctor, he prescribed a PSA (prostate-specific antigen) test for the early 
signs of prostate cancer, if you are a 40-year-old woman, your doctor prescribes the 
mammograms for the early signs of breast cancer, and if you are 50 years old, he 
prescribes the colonoscopy for colon cancer. Once the symptoms are revealed, the 
standard treatment is prescribed for a disease such as surgery, radiations treatment, 
or chemotherapy. The treatment after the appearance of its symptoms is considered 
as the reactive medicine.
A specific example is as follows: suppose your physician finds that you are sick 
with high temperature and high blood pressure, he prescribes Plavix a medicine of 
standard treatment for lowing your blood pressure and temperature. It is a reactive 
medicine. You receive treatment after your illness is diagnosed. Plavix is a useful 
drug for treating high blood pressure, but it does not respond in 15% of the patients. 
In treating reactive medicine, we do not really know what is going on in the body of 
those patients until after sequencing their genome, and identifying the abnormal 
mutation in their genetic makeup and then designing drugs to treat those patients is 
the true genomic medicine.
Predictive medicine, on the other hand, is the treatment of a disease long before 
its onset by examining your normal genomic script of the effected organ from 
your book of life and comparing its entire script with the genome of a sick patient. 
Spelling errors in our genome are the mutations responsible for causing diseases. 
The difference between the reactive medicine and the predictive medicine is 
whether you have the disease or you will come down with the disease because you 
are carrying a mutation which could become activated and make you sick. Genomic 
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medicine will have predictive quality. When comparing genome sequences, we find 
differences called variants. Good variants are responsible for our evolution, and 
abnormal variants are responsible for causing diseases. Using restriction enzymes 
(molecular scissors) like EcoR1, we can cut, paste, and copy a gene (conduct genetic 
engineering) and prepare a chart (called restriction site map) of all 6000 variants 
responsible for causing all 6000 diseases. By comparing the sequence of a genes 
from the chart, we can predict which specific gene variant is expected to cause 
which disease.
As cells grow, the mutations accumulate and defects in genotype manifests in 
phenotype. By using MRI (magnetic resonance imaging which provides three-
dimensional image) method, one could see the progressive microscopic abnormal 
changes in the nucleotide bases and predict the onset of a disease. The three-
dimensional MR imaging could serve as a diagnostic technique. Once the diagnosis 
is confirmed, drug design must begin to treat the disease. There are 220 different 
tissues in our body. We take the MRI of all 220 tissues of a healthy person and dur-
ing his annual medical checkup compare the present MRI with the previous years’ 
MRI to see any unusual microscopic changes predicting diseases. Once identi-
fied, the next logical step is to design drugs to shut off mutated genes to prevent 
diseases.
Genetic disorders can be caused by a mutation in one gene (monogenic disor-
der), by mutations in multiple genes (multifactorial inheritance disorder), by a 
combination of gene mutations and environmental factors, or by damage to chro-
mosomes (changes in the number of copies or structure of entire chromosomes, 
or part of the chromosome that carries genes). What specific nucleotide damage 
forming the codon is responsible for causing catastrophic diseases? By comparing 
the mutations in a DNA sequence (genotype), we can predict the onset of a disease 
in human (phenotype). The microscopic changes not detected by observations can 
be confirmed by three-dimensional MRI technique, which will diagnose diseases 
long before the symptoms appear.
To some degree, we have achieved the quantity control of the population by 
genome sequencing. Western countries are far ahead of the Eastern nations. The 
sequencing of the human genome provides rational approach to the quality control 
of the population. We have good news for those families who are suffering from 
severe heritable diseases generations after generations. Some of those rare allele 
diseases are mental diseases such as Parkinson, Huntington, schizophrenia, bipolar 
disorder, etc. often known as the Mendelian diseases. Those family members can 
still have children, but we recommend that they have conception by in vitro fer-
tilization, that is, they conceived children outside their bodies, that is, in the test 
tube. The fertilized egg is harvested in the incubators for 3 days until it grows from 
a single cell to eight number cells. Without any ill effect, one cell could be removed 
and its genome is sequenced. Suppose the sequenced cell identify abnormal muta-
tions when implanted will produce an incurably blind child or mentally retarded 
child. Is there a reason to bring this child into this intensely competitive world? 
Education is a very long process. To complete his education from age 5 to 25 years, 
when he completes his education and receives his Doctorate Degree, a child has to 
take several tests. If he fails one test, he is thrown out of the success train. No matter 
how painful it is on either religious or moral ground, we must ask ourselves a simple 
question. Does this fertilized ovum produce an acceptable member of the human 
society? If the answer is no, then we must throw out the defected ovum and use a 
new ovum. Out of eight, we have screened only a single cell. Should we sequence 
and select a cell for implantation which is free from all harmful mutations? Will 
society approve this reasonable request?
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5.1 Drug design for rare allele diseases
These are the diseases of people of all ages. Before the development of anti-
biotics, most people died of infectious diseases around age 50. First, antibiotics, 
penicillin (discovered by Alexander Fleming), was used for treating wounds before 
the WWII. As I said above, enormous funds were made available by the army to 
develop large-scale antibiotics to treat wounded soldiers returning from the battle 
ground during WWII. During the following decades, novel class of aminoglycoside 
antibiotics were discovered, which are valuable therapeutic agents. Some of them 
are streptomycin, neomycin, kanamycin, paromomycin, apramycin, tobramycin, 
amikacin, netilmicin, gentamicin, etc. Dozens of their water/fat-soluble deriva-
tives were synthesized. They are considered broad spectrum antibiotics because 
they inhibit the growth of both Gram-negative and Gram-positive bacteria causing 
deadly diseases and save human life. All aminoglycoside antibiotics are relatively 
small, basic, and water-soluble molecules that form stable salts. Most aminoglyco-
side antibiotics are products of fermentation of filamentous actinomycetes of the 
genus Streptomyces.
5.2 Drug design for common allele diseases
These are the diseases of old age people. Nowadays, people rarely die of infec-
tious diseases. Because of the availability of a variety of antibiotics, today, most 
people live beyond age 70 years and some of them go on living beyond 80 years of 
age. Those who live beyond 70 are faced with three major old age diseases, which 
are responsible for causing the death of most patients during their lifetime and they 
are cancers, cardiac diseases, and Alzheimer. These are genetic diseases and could 
be treated either by gene therapy (using CRISPER technology by replacing bad gene 
with the good gene using CRISPER-Cas9) or by drug therapy. There are about 3000 
monogenic diseases and could be treated by replacing the defected gene with good 
gene, that is, by gene therapy or designing drugs to shut off the bad genes that is 
drug therapy. Gene therapy cannot be applied to treat multiple genetic defects such 
as Alzheimer, cancer, and cardiovascular diseases. Drug therapy could be used to 
develop novel treatments. Recently completed 1000 Human Genome Project iden-
tify with precision and accuracy the genes responsible for causing these diseases. It 
is now possible to design drugs to shut off these genes and save human life. Genes 
code for proteins and a mutated gene codes for abnormal proteins resulting in these 
diseases.
6. Cancers
Cancer is the leading cause of death and has surpassed the death of cardiovas-
cular diseases. Over 636,000 people died of cancer; 1.9 million new cases will be 
diagnosed this year including 78,000 prostate cancer, 40,000 breast cancer, 16,000 
lung and bronchus cancer, and 15,000 colon and rectal cancer. Once diagnosed by 
gene sequencing, the next step is to design drug to shut off those genes.
6.1 The rational drug design to treat cancers
All three old age diseases, that is, cancer, cardiovascular diseases, and Alzheimer 
carry multiple mutated genes responsible for causing these diseases. In each of the 
above three diseases, it is the mutated genes that code for wrong protein which 
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causes these diseases. If we design drugs to shut off mutated genes in one disease, 
using the same rationale, we should be able to shut off bad genes in all three old age 
diseases. Although coronary artery disease is a complex disease, researchers have 
found about 60 genomic variants that are present more frequently in people with 
coronary artery disease. Most of these variants are dispersed across the genome 
and do not cluster on one specific chromosome. Drugs are designed to seek out the 
specific malignant gene, which replicates faster producing acids. Aziridines and 
carbamate moieties are sensitive to acid. Drugs carrying the aziridines and carba-
mate moieties are broken down in acidic media generating carbonium ions which 
attack DNA shutting off genes. Only the acid producing genes will be attacked no 
matter where they are located. It does not matter whether they are clustered or 
dispersed across genome.
The supreme intellect for drug design is Ross, an Englishman, who is a Professor 
of Chemistry at the London University. Professor WCJ Ross is also the Head of 
Chemistry Department at the Royal Cancer Hospital, a postgraduate medical 
center of the London University. Ross was the first person who designed drugs 
for treating cancers. He designed drugs to cross-link both strands of DNA that we 
inherit one strand from each parent. Cross-linking agents such as nitrogen mustard 
are extremely toxic and were used as chemical weapon during the First World 
War. More toxic derivatives were developed during the Second World War. Using 
the data for the toxic effect of nitrogen mustard used during the First World War, 
Ross observed that soldiers exposed to nitrogen mustard showed a sharp decline of 
white blood cells (WBC) that is from 5000 cell/CC to 500 cells/CC. Children suf-
fering from childhood leukemia have a very high WBC count over 90,000 cells/CC. 
In sick children, most of the WBCs are premature, defected, and unable to defend 
the body from microbial infections. Ross rationale was that cancer cells divide 
faster than the normal cell, by using nitrogen mustard to cross-link both strands 
of DNA, one can control and stop the abnormal WBC cell division in leukemia 
patients. It was indeed found to be true. Professor Ross was the first person to 
synthesize a large number of derivatives of nitrogen mustard. By using an analog 
of nitrogen mustard, called chlorambucil [9], he was successful in treating child-
hood leukemia. In America, two physicians named Goodman and Gilman from the 
Yale University were the first to use nitrogen mustard to treat cancer in humans. 
Nitrogen mustards and its analogs are highly toxic. Ross was a chemist; over the 
years, he synthesized several hundred derivatives of nitrogen mustard molecules to 
modify toxicity of nitrogen mustard [10–14].
Although analogs of nitrogen mustard are highly toxic, they are more toxic to 
cancer cells and more cancer cells are destroyed than the normal cells. Toxicity is 
measured as the chemotherapeutic index (CI), which is a ratio between toxicity to 
cancer cells versus the toxicity to normal cells. Higher CI means that the drugs are 
more toxic to cancer cell. Most cross-linking nitrogen mustard have a CI of 10, that 
is, they are 10 times more toxic to cancer cells. Some of the nitrogen mustard analogs 
Ross made over the years are useful for treating cancers such as chlorambucil for 
treating childhood leukemia (which brought down the WBC level down to 5000/CC). 
Childhood leukemia is the name of a disease occurs in children only. Chlorambucil 
made Ross one of the leaders of the scientific world. He also made melphalan and 
myrophine for treating pharyngeal carcinomas [15].
6.2 The discovery of AZQ (US Patent 4,146,622) for treating brain cancer
At the London University, I was trained as an organic chemist in the Laboratory 
of Professor WCJ Ross of the Royal Cancer Hospital, a postgraduate medical center 
of the London University. After working for about 10 years at the London University, 
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I moved to America when I was honored by the Fogarty International Fellowship 
Award by the National Institutes of Health, NIH, and the National Cancer Institute, 
NCI, of the USA. NIH has been my home for over a quarter of a century; I designed 
drugs to shut off mutated genes. All three common allele diseases have genetic 
origin. The rationale I used to synthesize anticancer drugs could be used to treat the 
other two old age diseases like Alzheimer and cardiovascular diseases. In the follow-
ing sections, I will describe in detail how anticancer drug like AZQ was designed 
to shut off glioblastoma genes which cause brain cancer in humans. Using the same 
rational, we will consider how each of the other two diseases, namely, cardiovascular 
disease and Alzheimer could be treated by shutting off their genes to save human 
life: The order of these diseases are arranged based on the level of funding provided 
by NIH specifically by the NCI (National Cancer Institute).
As I said above, Professor Ross was designing drugs to attack both strands of 
DNA simultaneously by cross-linking using nitrogen mustard analogs, which are 
extremely toxic. As a part of my doctoral thesis, I was assigned a different path. 
Instead of cross-linking DNA, I am to design drugs to attack only one strand of 
DNA. This class of drugs is called aziridines. Over the years, I made over 100 dini-
trophenyl aziridine derivatives. One of them is dinitrobenzamide (CB1954) which 
gives a CI of 70, highest ever recorded. CB1954 wipes out a solid tumor by attacking 
the DNA of Walker carcinoma 256, a solid aggressive tumor in rat.
Nitrogen mustards are highly toxic because they have neither specificity nor 
selectivity. They attack all dividing cells whether they are normal or abnormal. On 
the other hand, the analogs of aziridines and carbamates remain inactive in the basic 
and neutral media. They become activated only in the presence of acidic media.
I used a simple rationale, the aziridine attacks DNA in acidic medium, par-
ticularly the N-7 guanine. The dye dinitrobenzamide has great affinity for Walker 
tumor [16–18]. The aziridine dinitrobenzamide (CB1954) stains the tumor. As 
the tumor grows, it uses glucose as a source of energy. Glucose is broken down 
to pyruvic acid. It is the acid which attacks the aziridine ring. The ring opens to 
generate a carbonium ion, which attacks the most negatively charged N-7 guanine 
of DNA shutting off the Walker carcinoma gene in rat. To continue my work, I was 
honored with the Institute of Cancer Research Post-Doctoral Fellowship Award of 
the Royal Cancer Hospital of London University. To increase the toxicity of CB1954 
to Walker carcinoma, I made additional 20 analogs as a postdoctoral fellow. When 
I attached one more carbonium generating moiety, the carbamate moiety to the 
aziridine dinitrobenzene, the compound aziridine dinitrobenzamide carbamate was 
so toxic that its therapeutic index could not be measured. We stopped the work at 
the London University for the safety concern.
I continued my work on the highly toxic aziridine/carbamate combination in 
America when I was offered the Fogarty International Fellowship Award to con-
tinue my work at the National Cancer Institute (NCI) of the National Institutes of 
Health (NIH). I brought the idea from London University of attacking one strand 
of DNA using not only aziridine, but also carbamate without using the same dye 
dinitrobenzamide [19–21].
My greatest challenge at NCI is to translate the animal work which I did in 
London University to humans. One day, I came across a paper which described 
that radiolabeled methylated quinone cross the blood-brain barrier in mice. When 
injected in mice, the X-ray photograph showed that the entire radioactivity was 
concentrated in the mice’s brain within 24 hours. I immediately realized that glio-
blastoma multiforme, the brain tumor in humans, is a solid aggressive tumor like 
Walker carcinoma in rats. I decided to use quinone moiety as a carrier for aziridine 
rings to attack glioblastomas. By introducing an additional carbamate moiety, I 
could increase its toxicity several folds. I planned to use this rational to translate 
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animal work to human by introducing multiple aziridine and carbamate moieties 
to the quinone to test against glioblastomas in humans. Attaching two aziridines 
and two carbamate moieties to quinone, I made AZQ. By treating brain cancer with 
AZQ, we observed that glioblastoma tumor not only stop growing but also start 
shrinking. I could take care of at least one form of deadliest old age cancers, that is, 
glioblastomas. Literature search showed that AZQ is extensively studied.
As I said above, glioblastoma, the brain cancers, is a solid and aggressive tumor 
and is caused by mutations on several chromosomal DNA. Mutations on DNA are 
the result of damaging DNA nucleotides by exposure to radiations, chemical and 
environmental pollution, viral infections, or genetic inheritance. The other fac-
tors responsible for causing DNA mutations are due to the fast rate of replication 
of DNA. For example, the bacteria E. coli grows so rapidly that within 24 hours, a 
single cell on a petri dish forms an entire colony of millions when incubated on the 
agar gel. Rapid replication is responsible for introducing genetic defects causing 
diseases.
When an additional piece of nucleotide is attached to a DNA string, it is called 
insertion or a piece of DNA is removed from the DNA string; it is called deletion or 
structural inversion of DNA is responsible for mutations. Since the gene in a DNA 
codes for proteins, insertion and deletion on DNA have catastrophic effects on 
protein synthesis. Glioblastomas represent such an example. In glioblastomas, three 
major changes occur on chromosomes (C-7, C-9, and C-10) and two minor changes 
occur on chromosomes (C-1 and C-19). These mutations are responsible for causing 
brain cancers in humans. In a normal human cell, chromosome-7 which is made of 
171 million nucleotide base pairs and carries 1378 genes. When insertion occurs on 
chromosome-7, 97% of glioblastoma patients are affected by this mutation. On the 
other hand, a different mutation occurs on chromosome-9 which is made of 145 
million nucleotide base pairs and it carries 1076 genes. A major deletion of a piece 
of DNA occurs on chromosome-9, which results in 83% patients who are affected 
by this mutation. A minor deletion of DNA also occurs on chromosome-10 which is 
made of 144 million base pairs and it carries 923 genes. Although it is a minor dele-
tion of a piece of DNA, it contributes to 91% patients with glioblastoma. To a lesser 
extent, small mutation occurs on chromosome-1 (the largest chromosome in our 
genome). It is made of 263 million nucleotide base pairs and carries 2610 genes), 
and chromosome-19 (it is made of 67 million base pairs and carries 1592 genes) is 
also implicated in some forms of glioblastomas.
All known glioblastomas causing genes are located on five different chromo-
somes and carries a total of 9579 genes. It appears impossible to design drugs to 
treat glioblastomas since we do not know which nucleotide on which gene and on 
which chromosome is responsible for causing the disease. With the completion of 
1000 Human Genome Project, it becomes easier. By simply comparing the patient’s 
chromosomes with the 1000 genomes, letter by letter, word by word, and sentence 
by sentence, we could identify the difference called the variants with precision and 
accuracy, the exact variants or mutations responsible for causing the disease. Once 
the diagnosis is confirmed, the next step is how to treat the disease.
With the quinone ring, I could introduce different combinations of aziridine 
rings and carbamate moieties and could create havoc for glioblastomas. My 
major concern was how toxic this compound would be to the human brain cells. 
Fortunately, brain cells do not divide, only cancer cells divide.
Our rational drug design work began in the University of London, England, and 
completed in the Laboratory of the National Cancer Institute (NCI), of the National 
Institutes of Health (NIH), in Bethesda, Maryland, USA. Over this period, we 
conducted over 500 experiments which resulted in 200 novel drugs. They were all 
tested against the experimental animal tumors. Forty-five of them were considered 
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valuable enough to be patented by the US Government (US Patent 4,146,622). One 
of them is AZQ. Radiolabeled studies showed that AZQ has the ability to cross organ 
after organ, cross the blood-brain barrier, cross the nuclear membrane, and attack 
the nuclear DNA shutting off the gene. X-ray studies showed that the radioactivity 
is concentrated in the tumor region. Glioblastoma stop growing and start shrinking. 
For the discovery of AZQ, I was honored with the “2004 NIH Scientific Achievement 
Award,” one of America’s highest awards in Medicine and I was also honored with 
the India’s National Medal of Honor, “Vaidya Ratna,” a gold medal (see Figures 1–4).
Figure 1. 
2004 NIH Scientific Achievement Award presented to Dr. Hameed Khan by Dr. Elias Zerhouni, the director 
of NIH during the NIH/APAO award ceremony held on December 3, 2004. Dr. Khan is the discoverer of AZQ 
(US Patent 4,146,622), a novel experimental drug specifically designed to shut off a gene that causes brain 
cancer for which he receives a 17-year royalty for his invention (license number L-0I9-0I/0). To this date, more 
than 300 research papers have been published on AZQ. The award ceremony was broadcast live worldwide by 
the Voice of America (VOA). Dr. Khan is the first Indian to receive one of America’s highest awards in Medicine.
Figure 2. 
His excellency, Dr. A.P.J. Abdul Kalam, the President of India greeting Dr. A. Hameed Khan, discoverer 
of anticancer AZQ, after receiving 2004, Vaidya Ratna, the gold medal, one of India’s highest awards in 
Medicine at the Rashtrapati Bhavan (Presidential Palace), in Delhi, India, during a reception held on 
02 April 2004.
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Figure 4. 
Gold medal for Dr. Khan. Dr. A. Hameed Khan, a scientist at the National Institutes of Health (NIH), USA, 
an American scientist of Indian origin was awarded on April 2, 2004. Vaidya Ratna, the gold medal, one of 
India’s highest awards in Medicine for his discovery of AZQ (US Patent 4,146,622) which is now undergoing 
clinical trials for treating bran cancer.
Figure 3. 
Single-strand DNA binding aziridine and carbamate.
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7. Cardiovascular diseases
Coronary artery disease is complex involving about 60 genomic variants 
(genes). All variants are not clustered on any specific chromosome. These vari-
ants are dispersed across the entire genome. Although all variants have not been 
sequenced, we can shut off only the mutated gene without knowing the sequence 
of all other genes. As I mentioned above in the “Cancers” section, the mutated gene 
grows rapidly forming the tumor. As it grows, it uses glucose as a source of energy, 
which is broken down to produce pyruvic acid. In the presence of acid, the analogs 
of aziridine and carbamate are activated to generate carbonium ion which attack 
the tumor DNA shutting off their genes. While we may someday be able to sequence 
all 60 genes associated with the coronary artery disease, presently, we can single 
out and identify the mutated gene bound complex using radiolabeled aziridine and 
carbamate. The following example explains how some arrhythmias causing genes 
could be identified and how drug could be designed to shut off these genes.
The term “QT” refers to the segment of an electrocardiogram, which measures 
the duration of time for the heart to relax after a heartbeat. In long QT syndrome, 
the duration of time is abnormally prolonged and creates a vulnerability to danger-
ous arrhythmias [22]. Ever since the syndrome was described in 1957, research-
ers have engaged in a genetic race to identify the genes associated with long QT 
syndrome, which currently includes 17 genes. Three genes, KCNQ1, KCNH2, and 
SCN5A, had sufficient evidence to be implicated as “definitive” genetic causes for 
typical long QT syndrome. Four other genes had strong or definitive evidence sup-
porting their role in causing atypical forms of long QT syndrome, presenting in the 
newborn symptoms associated with heart block, seizures, or delays in development. 
Once the mutated genes are identified, we could design drugs to shut off these 
genes as described in the “Cancers” section.
8. Alzheimer
In 1906, the German physician scientist Dr. Alois Alzheimer identified the 
microscopic changes in the brain of a patient with the memory loss. He was the first 
physician to identify the disease in a 50-year-old woman who suffered from psy-
chosis and who died within 4 years. Using special dyes, he stained the brain tissues 
which carried abnormal protein deposit around her brain which controlled brain 
function. He identified two kinds of legions of amyloid patches which he mistak-
enly thought was fatty patches and now turned out to be proteins. He observed a 
patch of fatty deposit on the top of the brain cells called plaques and the legions 
inside the nerve cells called tangles. He accurately correlated the abnormal protein 
deposits around brain cells with the controlled of brain function [23–26].
Today, we know that the age is the single most risk factor for developing 
Alzheimer. By age 65 or older, the risk for developing Alzheimer is about 10%, 
and by age 85 or older, the risk factor is as high as 40 or 50%. As people grow old, 
they become senile. When he performed the autopsy of many senile persons, Dr. 
Alzheimer found the same plaques and tangles in many other samples. Early onset 
or late onset of Alzheimer resulted in the epidemic of Alzheimer. When compar-
ing a normal brain with the Alzheimer brain, we find that the Alzheimer brain 
has shrunken and there is a concentration of plaques and tangles in neurons. In 
healthy brain cells, we see occasional plaques and tangles. It defines the disease; the 
plaque and tangles start building up as we grow old, and over years and decades, the 
symptoms begin to develop. Symptoms include memory loss and decrease in ability 
of learning and recall. Early onset affects cognition which encompasses memory 
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and other mental functions such as erosion of attention, thinking, reasoning, visual 
functions, spatial function, and dementia with memory loss and other cognitive 
functions resulting in mental impairment which affects to the degree interfering 
with the daily life.
Recent studies confirm that Alzheimer is an irreversible brain disorder which 
slowly destroys memory and thinking skills. The damage to the brain is not par-
ticularly associated to any specific gene, but the presence of the one form of the 
apolipoprotein E (APOE) is a suspect gene whose presence does increase a patient’s 
risk for developing Alzheimer. The early onset of Alzheimer is associated with 
three single gene mutations: first, the presence of an amyloid precursor protein 
(APP) located on chromosome-21; the presence of presenilin 1 (PSEN1) on chro-
mosome-14 and the presence of presenilin 2 (PSEN2) located on chromosome-1. 
All three chromosomes are very large and carry hundreds of genes. For example, 
chromosome-1 is the largest chromosome in the genome. It is made of 163 mil-
lion nucleotide bases carrying 2610 genes. Chromosome-21 is made of 50 million 
nucleotide bases carrying 337 genes, while chromosome-14 is made of 109 million 
nucleotide bases carrying 1173 genes.
A recent 7 million Utah population study identified two additional genes RAB10 
located on chromosome-2 (which is made of 155 million nucleotide bases and carry 
1798 genes) and SAR1A gene located on chromosome-10 (which is made of 144 mil-
lion nucleotide bases and carry 983 genes) associated with the formation of plaques 
and tangles. Mutations on these genes may be associated with the onset of Alzheimer.
Of all the genes on these chromosomes, only five single-gene mutations are 
associated with the early onset of the Alzheimer, it is the greatest challenge to 
design drugs to attack only the mutated genes. As I said above in the “Cancers” 
section, the good news is that the only mutated genes grow rapidly using glucose 
as a source of energy. Glucose is broken down to produce pyruvic acid. It is the acid 
which activates the aziridine and carbamate moieties producing powerful carbo-
nium ion which attack N-7 guanine of DNA and shut off only the mutated genes. 
Other genes are not affected. Using C-14 radiolabeled aziridines, we can identify 
the mutated gene which form the aziridine/protein complex as described in the 
“Cancers” section.
9. Rationale for designing drugs to treat Alzheimer
It is well known that using the TFT dye, which is 3,6-dimethyl-2-(4-
dimethlaminophenyl)-benzothiazoline, could be used to stain the plaques and 
tangles of Alzheimer tissues. Using TFT dye as a carrier for the aziridine and 
carbamate moieties, we could design drugs to attack the mutated DNA to shut off 
genes which form plaques and tangles to prevent the progress of Alzheimer.
In the above “Cancers” section, I have described in detail how I had used 
quinone as a carrier for aziridine and carbamate ions in designing AZQ to attack the 
brain tumor DNA to shut off genes for treating brain cancer. Similarly, the analogs 
of benzothiazoline dyes could be used to carry aziridine and carbamate moieties 
to attack the plaque and tangle DNA and shut off genes responsible for causing 
Alzheimer.
10. What other cancers should we explore next?
Could I use the same rational drug design and introduce a novel method for 
treating breast tumor?
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Although mutations on BRCA1 gene located on chromosome-17 (which is made 
of 92 million nucleotide bases carrying 1394 genes) have been identified years ago 
responsible for causing breast cancer, we wonder why it has been so difficult to 
design drugs on rational basis to treat breast cancer. By the time the breast cancer 
diagnosis is confirmed in a patient, the BRCA1 has accumulated more than 3000 
mutations. Genotyping of the blood would also show the existence of many cells 
carrying mutated cells responsible for creating secondary deposits. It is also believed 
that by the time breast cancer is confirmed, metastatic cancer cells have already been 
spread from liver lung on its way to brain. Since all other organs including breast and 
liver could be removed and replaced by organ transplant except brain, I thought that 
protecting brain is utmost important to save life. Once AZQ is developed to protect 
the brain, I could focus on the breast and prostate cancers.
Recent, radiolabeled studies showed that male hormone testosterone has great 
affinity for female organs like breast, ovary, and fallopian tube cells. On the other 
hand, estrogen, the female hormone, has great affinity for male prostate gland. By 
attaching multiple aziridine rings and carbamate ions to both hormones, I could 
design novel drugs to attack the breast and the prostate cancer. Now, I found that I 
could go even further by attaching more than four aziridine and carbamate moieties 
to both male and female hormones.
In a breast tumor, within the start and stop codons, BRCA1 gene has captured 
over 200,000 nucleotide bases. The BRCA1 genes carry about 3000 mutations. 
These mutations are caused by exposure to radiations, chemical or environmental 
pollutants, viral infection, or genetic inheritance. To attack the mutated nucleotides 
among the 3000 cells in BRCA1 gene, I could use male hormone, testosterone, 
and bind multiple radiolabeled aziridine and carbamate ions to attack BRCA1 
mutations. By using three-dimensional MRI, I could show how many radiolabeled 
nucleotides were bound to which mutations. Out of 17 positions available for sub-
stitutions on testosterone ring system, there are only three positions, that is, 1, 3, 
and 17 available for substitution on testosterone ring system. Carl Djerassi [27] had 
demonstrated that we could activate positions 9 and 10 by reacting with bromoacet-
amide which introduces a bromo ion on position 10 which could be de-brominated 
by collidine to introduce a 9,10 double bond which we could further brominate to 
produce 9,10 dibromo compound. This bromo ion could be replaced by additional 
aziridine or carbamate ions. I could increase or decrease the number of aziridine 
and carbamate ions to get the maximum benefit by further brominating positions 
15 and 16 to introduce additional aziridine and carbamate moieties.
Similarly, I could use the female hormone estrogen and by attaching multiple 
aziridine and carbamate ions to attack prostate tumor. Since there are 17 posi-
tions also available on estrogen ring as well; again, I could increase or decrease the 
number of aziridine and carbamate ions to get the maximum benefit.
11. Ethical issues (the impact of science on society)
By 2050, novel drug design would have produced new class of medicine to treat 
all known 6000 genes. We would not only produce new treatment but also we 
would have new food, new fuel, and new medicine to treat every disease known 
to mankind to protect, preserve, and prolong human life beyond 100 years. This 
section discusses the impact of prolonging human life beyond 100 years.
Our attempt to prolong human life by shutting off the genes of the old age 
diseases raises several ethical and moral questions. We face the same population 
problem when we succeed in shutting off genes of all three old age diseases, that 
is, cancer, cardiovascular disease, and Alzheimer. Most people will live longer and 
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happier life. It raises several questions. What happens after we achieve that goal of 
reaching 100 years? What would be the quality of our life? By exercises and good 
nutrition, if the body mass is not retained, the centenarians are most likely to be 
fragile and weak. They need the help of caretakers to perform the daily routine. By 
2050, if we increase the age of about 100 years of about a billion people, we need 
another billion caretakers. Will the society be happy with this achievement? I doubt 
it. The society is hardly likely to accept such a proposal.
To cure diseases to prolong human life, several present and future attempts are 
described below.
We need to make two rationale approaches: first, to identify rare allele in the 
genome of centenarians responsible for prolonging their lives. Once identified the 
allele, we need to conduct genetic engineering, that is, to cut, paste, copy, and splice 
the allele into the genome of volunteers to study its function. Second approach is to 
design drugs to shut off genes of old age to prolong life.
Next attempt to increase human life would be to prevent the loss of telomeres, 
the six-letter code (TTAGGG) that shorten our DNA and shorten our lifespan. 
During replication, each chromosome loses about 30 telomeres each year. If we 
prevent the loss of telomeres by using the enzyme telomerase reverse transcriptase 
(TRT), we could slow down the aging process. We have already demonstrated in 
the worm C. elegance that we could increase its lifespan several fold. Now, we could 
translate this work in human being; we could try by making a less virulent flu virus 
carrying TRT gene when injected to a volunteer who comes down with a mild flu. 
When he recovers from the flu, the TRT gene would have inserted in the entire 
genome of every cell in his body (we can confirm the insertion by sequencing). 
Suppose at each replication, only 15 telomeres are deleted instead of 30 telomeres. 
This person is likely to live twice as long. Also, suppose the sequencing of his 
genome would confirm that every cell of his body carries the TRT gene. Since the 
longevity treatment with the flu virus is safe, inexpensive, and would be easily 
available to everyone, should we provide the treatment to every man, woman, and 
child on the face of the Earth?
Such studies are likely to raise two serious ethical questions. First, we have to ask 
ourselves, do people have a right to live and second do we have a right to live as long 
as we wish, no matter how old, how weak, or how sick we are? The answer to first 
question is, according to the UN charter, we all have the right to life, liberty, and 
pursuit of happiness. It is the second question which is troublesome. Do people have 
a right to extent their lives as long as they wish? Most people are reluctant to answer 
this question either No or Yes. Both answers have some support.
Those who said No have a good reason. First, they argue that there are seven and 
a half billion people live on planet Earth and we are adding 90 million additional 
people each year. According to UN estimate, by 2050, the population of the world 
is likely to reach 9 billion. Does our planet Earth have all resources to support such 
a population explosion? Can we provide food, fuel, and medicine to all the people 
of the world? In poor countries, millions are starving now. By extending life, we 
will have serious problems such as lawlessness, riots, and chaos in the streets. The 
current population of Earth has polluted the water, the air, and the land. Today, 
they wonder if the water they drink is safe, the food they eat is safe, and the air they 
breathe is safe. If we continue to pollute the planet with the current rate which is 
110 million ton of pollutant that we release in the atmosphere each year, how much 
pollutants we would accumulate in the atmosphere in 10 years or in 100 years.
On the other hand, those who say Yes; we should extend life have good reasons 
as well. We have no Plan B to save human life on some other planet. We look up 
to Heaven to find another home for humanity. To search for a suitable planet for 
human life to survive, we need to train an army of astronauts to travel into deep 
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space with extended life span. They may have to travel for centuries to find a habit-
able planet for humans. We do not want them to die on their way to find a new home 
for humanity. We must continue to search for treatment to prolong human life.
What if we succeed tomorrow in developing treatment of all three old age 
diseases to double or triple our lifespan? If we do not succeed tomorrow may be day 
after tomorrow. Say the treatment is safe, inexpensive, and easily available to every 
man, woman, and child on the face of the Earth. Who decide that person A will 
receive the longevity treatment and will live and person B will not receive the same 
treatment and therefore will die? We need debate and discussion and come up with 
guidelines for our society. One person cannot provide answer to all these questions. 
All I want to do is to raise these questions in your mind. My aim will be fulfilled if I 
have made you think along these lines.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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